GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION Russian patent published in 2016 - IPC G01N33/50 C12Q1/68 

FIELD: medicine.

SUBSTANCE: what is presented is a method for prediction of a high probability of the therapeutic effect of high-affinity anti-VEGF antibody, particularly ranibizumab in the patient with wet age-related macular degeneration (AMD). What is presented is a kit comprising a first oligonucleotide and second oligonucleotides specific for alleles of BATF gene polymorphism rs175714. If the genotype occurs to contain AA or AG, the high probability of the therapeutic effectiveness is predicted in the patient.

EFFECT: effective agents and methods for prediction of the high probability of the therapeutic effectiveness in the patients with wet AMD.

9 cl, 1 dwg, 5 tbl, 1 ex